Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review.
Stijn HentzenTomer MeirsonKelly KoehnAaron GoodmanRajshekhar ChakrabortyDouglas SborovSamuel RubinsteinGhulam Rehman MohyuddinPublished in: European journal of haematology (2023)
Although progression is the most common reason for RCT treatment discontinuation in patients with MM, over 10% discontinued due to toxicity. Furthermore, 24.4% of trials showed substantial imbalances between trial cohorts; raising concern for informative censoring and emphasizes the importance of detailed characterization of withdrawal in MM RCTs.